Press Release Archive

Innovation July 17, 2018

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Our Company July 17, 2018

Johnson & Johnson Reports 2018 Second-Quarter Results:

Johnson & Johnson Reports 2018 Second-Quarter Results:
Innovation July 16, 2018

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings

Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
July 16, 2018

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2018
Innovation July 13, 2018

U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application

U.S. FDA Extends Review Timeline for INVOKANA® (canagliflozin) Supplemental New Drug Application
Our Company July 13, 2018

Johnson & Johnson’s Official Statement in Response to Today’s Verdict in St. Louis Trial

Johnson & Johnson’s Official Statement in Response to Today’s Verdict in St. Louis Trial
Innovation July 11, 2018

Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)

Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL)
Innovation July 06, 2018

Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV

Johnson & Johnson Announces Publication in The Lancet Highlighting Robust Immune Response to Janssen’s Mosaic-based Preventive Vaccine Regimen for HIV
Innovation June 26, 2018

Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation

Champions of Science: The Art of Ending Stigma Project Launches to Combat Stigma About Mental Illnesses Through Education and Artistic Creation
Innovation June 24, 2018

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

Real-World Study of More than 700,000 People with Type 2 Diabetes (T2D) Shows No Increased Risk of Below-Knee Lower Extremity Amputations with INVOKANA® (canagliflozin) Compared to Other Diabetes Medications

See More Press Releases